| Literature DB >> 30025348 |
Martín Estrada Valencia1, Clara Herrera-Arozamena1, Lucía de Andrés1, Concepción Pérez1, José A Morales-García2, Ana Pérez-Castillo3, Eva Ramos4, Alejandro Romero4, Dolores Viña5, Matilde Yáñez6, Erik Laurini7, Sabrina Pricl7, María Isabel Rodríguez-Franco8.
Abstract
In this work we describe neurogenic and neuroprotective donepezil-flavonoid hybrids (DFHs), exhibiting nanomolar affinities for the sigma-1 receptor (σ1R) and inhibition of key enzymes in Alzheimer's disease (AD), such as acetylcholinesterase (AChE), 5-lipoxygenase (5-LOX), and monoamine oxidases (MAOs). In general, new compounds scavenge free radical species, are predicted to be brain-permeable, and protect neuronal cells against mitochondrial oxidative stress. N-(2-(1-Benzylpiperidin-4-yl)ethyl)-6,7-dimethoxy-4-oxo-4H-chromene-2-carboxamide (18) is highlighted due to its interesting biological profile in σ1R, AChE, 5-LOX, MAO-A and MAO-B. In phenotypic assays, it protects a neuronal cell line against mitochondrial oxidative stress and promotes maturation of neural stem cells into a neuronal phenotype, which could contribute to the reparation of neuronal tissues. Molecular modelling studies of 18 in AChE, 5-LOX and σ1R revealed the main interactions with these proteins, which will be further exploited in the optimization of new, more efficient DFHs.Entities:
Keywords: Donepezil-flavonoid hybrids; Human 5-lipoxygenase; Human acetylcholinesterase; Human monoamine oxidases; Neurogenesis; Neuroprotection; Sigma receptors
Mesh:
Substances:
Year: 2018 PMID: 30025348 DOI: 10.1016/j.ejmech.2018.07.026
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514